Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2013 - 2026)

Amphastar Pharmaceuticals' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $164.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 17.37% year-over-year to $164.5 million; the TTM figure through Mar 2026 stood at $164.5 million (down 17.37% YoY), while the FY2025 annual figure was $158.2 million, down 8.98% from the prior year.
• Total Current Liabilities was $164.5 million for Q1 2026 at Amphastar Pharmaceuticals, up from $158.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $258.0 million in Q3 2023 to a low of $94.9 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $169.6 million across 5 years, with a median of $164.5 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 152.43% in 2023, then plunged 45.49% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $94.9 million in 2022, then surged by 137.62% to $225.4 million in 2023, then slipped by 22.91% to $173.8 million in 2024, then declined by 8.98% to $158.2 million in 2025, then gained by 4.0% to $164.5 million in 2026.
• The last three Total Current Liabilities figures came in at $164.5 million (Q1 2026), $158.2 million (Q4 2025), and $205.2 million (Q3 2025), per Business Quant data.